FDA Approves MannKind's Afrezza for Pediatric Diabetes Patients
Decision brief
Answer first · skim in under a minute
The US FDA has approved MannKind's Afrezza inhaled insulin for pediatric patients aged 6 and older diagnosed with Type 1 or Type 2 diabetes. This approval marks a significant expansion for the inhaled insulin.
On May 29, 2026, the U.S. FDA approved MannKind’s Afrezza (insulin human) Inhalation Powder for children and adolescents aged 6 and older with type 1 or type 2 diabetes, expanding the 2014 adult label with Phase 3 INHALE-1 evidence and closing the last postmarketing requirement tied to the original approval.
Contents10 sections
Key Takeaways
- FDA pediatric approval for Afrezza: May 29, 2026, ages 6+ with type 1 or type 2 diabetes (MannKind 8-K; GlobeNewswire).
- U.S. pediatric diabetes burden cited by MannKind: more than 350,000 children and adolescents.
- Pivotal support: Phase 3 INHALE-1 (NCT04974528), completed with 319 enrolled (ClinicalTrials.gov).
- FDA stated the pediatric sBLA fulfilled the last postmarketing requirement from the June 27, 2014 approval letter.
What did the FDA approve for Afrezza on May 29, 2026?
The FDA approved Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes, MannKind reported in its Form 8-K dated May 29, 2026.
The same day, MannKind’s GlobeNewswire release described Afrezza as an ultra rapid-acting inhaled mealtime insulin delivered via Technosphere technology at the start of a meal.
Which clinical evidence backed the pediatric Afrezza label?
MannKind said approval was supported by the pivotal Phase 3 INHALE-1 trial plus longer-term inhaled-insulin safety and efficacy experience. ClinicalTrials.gov records for NCT04974528 list the study title “Afrezza® INHALE-1 Study in Pediatrics,” status COMPLETED, actual enrollment 319, start September 29, 2021, and completion April 29, 2025.
Independent trial registry details should be used to verify design claims such as arm comparisons and endpoint definitions; sponsor press language alone is not a substitute for the protocol record.
How does the pediatric label change Afrezza’s U.S. status?
Afrezza was first FDA-approved in June 2014 for adults 18 and older. The May 2026 decision expands availability to ages 6 and older, according to MannKind’s GlobeNewswire announcement and 8-K.
- Population cited: more than 350,000 U.S. children and adolescents with diabetes.
- Type 1 diabetes remains the majority of that pediatric burden in MannKind’s filing language.
- Label still requires basal insulin in people with type 1 diabetes; Afrezza is not for diabetic ketoacidosis.
- Boxed-warning class risks include acute bronchospasm; chronic lung disease such as asthma or COPD is a contraindication in the Important Safety Information MannKind republished.
What commercial access claims did MannKind make?
In the May 29, 2026 GlobeNewswire release, MannKind said eligible patients can access Afrezza for $35 or less per month and pointed caregivers to MannKind Cares support. Those are company access-program statements, not FDA label requirements or independent pricing audits.
Coverage, prior authorization, and out-of-pocket costs will still vary by plan and pharmacy channel after the pediatric indication is listed.
How should BD and medical teams read the filing trail?
Start with the SEC 8-K for the regulatory fact pattern: approval date, age band, and the closed postmarketing requirement. Then cross-check the GlobeNewswire release for access-program claims such as the $35 monthly statement. Finally, open NCT04974528 to confirm enrollment (319) and completion (April 29, 2025) before you model uptake.
That three-source stack keeps analyst notes tied to allowlisted records. It also separates label expansion from marketing language about school schedules, sports, or “first and only” positioning.
What remains unproven after the pediatric nod?
The approval establishes regulatory authorization for ages 6+. It does not prove better long-term outcomes versus pumps or rapid-acting injectables in every pediatric clinic.
INHALE-1 enrollment and completion are registry facts. Comparative effectiveness outside the protocol, school-day adherence, and lung-function monitoring in broader pediatric use still need post-approval evidence.
MannKind’s “first and only” inhaled mealtime insulin claim for this age group is competitive positioning tied to current FDA labeling. It is not a clinical superiority finding.
Related NovaPharma coverage
- Insulin recombinant human drug profile
- FDA approves lumasiran for acute hepatic porphyria
- FDA approves Vertex Journavx for acute pain
Frequently Asked Questions
When did the FDA approve Afrezza for children?
On May 29, 2026, the FDA approved Afrezza (insulin human) Inhalation Powder for children and adolescents aged 6 and older with type 1 or type 2 diabetes, according to MannKind’s Form 8-K and GlobeNewswire release.
What trial supported the Afrezza pediatric label?
The Phase 3 INHALE-1 study (NCT04974528) supported the pediatric indication. ClinicalTrials.gov lists the study as completed, with an actual enrollment of 319 participants and a primary completion date of April 29, 2025.
What postmarketing obligation did the pediatric approval close?
MannKind’s May 29, 2026 Form 8-K states the FDA said the supplemental biologics license application for the pediatric indication fulfilled the last remaining postmarketing requirement from Afrezza’s original June 27, 2014 approval letter.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Afrezza.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
